
Sign up to save your podcasts
Or


(00:32):
Before we jump in, would each of you share a little bit about your background and yourselves?
(01:18):
Dr. Marcou. could you provide us with an overview of what the WESDX test is?
(01:50):
Marissa, would you help explain why this test is important?
(03:10):
In your experience who would benefit from WESDX,
(05:12):
How does a provider order A WES DX and secondarily what type of samples are accepted?
(06:24):
What types of variants are detected by the test?
(07:47):
There are a lot of exome tests available. What are some other unique features that set WESDX apart?
(09:52):
Last question, could you summarize the benefits of doing WESDX at Mayo?
(00:32)
Could you let our listeners know a bit about your role and background at Mayo Clinic?
(01:23)
Is there a lot of information sharing between our neurology clinicians and the Alzheimer’s Disease Research Center when it comes to test development?
(01:50)
Can you give us a brief overview of the test?
(03:17)
Is a cerebral spinal fluid test for NFLC already on the market?
(04:41)
How has Mayo Clinic been able to launch this test in blood?
(05:49)
What is a laboratory developed test, and what does it mean for physicians?
(07:00)
Do we have a high degree of confidence that physicians will get an actionable result from this blood test?
(07:45)
How will Mayo Clinic Laboratories help physicians interpret the test results?
(09:15)
For which patients is this test most appropriate?
(10:59)
How might patients benefit from this test?
(11:46)
How can this test help physicians to know which treatment path to pursue?
(12:33)
How else might this test benefit patients?
(13:49)
What about this test excites you most?
From the publisher's feed

31,921 Listeners

3,170 Listeners

11,857 Listeners

10,640 Listeners

111,764 Listeners

56,420 Listeners

46,744 Listeners